Bairen Medical Subsidiary's Cross-Linked Collagen Implant Approved

Regulation
โดย 财中社·Read original
Summary · why it matters

The cross-linked collagen implant, also known as Collagen Fiber Filler II, developed by Bairen Medical's controlled subsidiary Beijing Aiborui Biotechnology Co., Ltd., has received registration approval. This product is the second approved item in Aiborui's collagen series, following Collagen Fiber Filler I. In the first quarter of 2026, Bairen Medical achieved revenue of 144 million yuan and a net profit attributable to the parent company of 41.38 million yuan.

Impact on stocks 1

© 2026 MarketDXNews